Atypical cutaneous vasculitis under lapatinib

European Journal of Dermatology

Volumn 23, Issue 4, 2013, Pages 540-541

  Peuvrel, Lucie ^a   Quereux, Gaëlle ^a   Brocard, Anabelle ^a   Saint Jean, Mélanie ^a   Freour, Elisabeth ^a   Josselin, Nicolas ^b   Audouin, Anne Françoise ^b   Kouri, Claude El ^c   Dreno, Brigitte ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Institut d'Histopathologie   (France)

^c Department of Oncology ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; LAPATINIB; NAVELBINE; PACLITAXEL; PREDNISONE; TRASTUZUMAB; VALACICLOVIR;

ADULT; BREAST ADENOCARCINOMA; CASE REPORT; DEATH; DIFFERENTIAL DIAGNOSIS; FEMALE; FEVER; FOLLOW UP; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; LETTER; LEUKOCYTOCLASTIC VASCULITIS; LIVER METASTASIS; MASTALGIA; SKIN BIOPSY; TUMOR GROWTH;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG ERUPTIONS; FATAL OUTCOME; FEMALE; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; QUINAZOLINES; VASCULITIS;

EID: 84884386830     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2013.2080     Document Type: Letter

References (10)

1. Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007; 12: 756-765.
2. von Minckwitz G, Eidtmann H, Loibl S, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2011; 22: 301-6.
3. Lacouture ME, Laabs SM, Koehler M, et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2009; 114: 485-493.
4. Nardone B, Nicholson K, Newman M, et al. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. Clin Cancer Res 2010; 16: 4452-4460.
5. Janne PA, Boss DS, Camidge DR, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011; 17: 1131-1139.
6. Zinner RG, Nemunaitis J, Eiseman I, et al. Phase I clinical and phar-macodynamic evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res 2007; 13: 3006-3014.
7. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13:528-538.
8. Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:3076-3083.
9. Ko JH, Shih YC, Hui RC, Yang CH. Necrotizing vasculitis triggered by gefitinib: an unusual clinical presentation. J Clin Oncol 2011; 29:e169-170.
10. Boeck S, Wollenberg A, Heinemann V. Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib. Ann Oncol 2007;18:1582-3.